clinical trial · NCT06072482
A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis
Antineutrophil Cytoplasmic Antibody-associated VasculitisAvacopanPlaceboStandard of Care
brief summary
The primary objective of this study is to evaluate the long-term safety of avacopan in participants with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).
started
Feb 7, 2024
primary completion
Dec 31, 2036
completion
Dec 31, 2036
last updated
Jun 12, 2026
official title
A Randomized, Double-blind, Placebo-controlled Phase 4 Clinical Trial to Evaluate the Long-term Safety and Efficacy of Avacopan in Participants With Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol